NCT00630149

Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy

Open-Label Single-Arm Phase 2 Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Had Prior Platinum Based Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a pilot phase II study of locally advanced or metastatic nasopharyngeal carcinoma (NPC) with the single drug Alimta. The objective of this study is to assess efficacy and safety profiles of Alimta as 2nd line treatment for patients with advanced NPC.

Conditions

• Nasopharyngeal Neoplasms

Interventions

Type	Name	Description
DRUG	Pemetrexed (Alimta)	500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.

Timeline

• Start date: 2007-11-01
• Primary completion: 2011-11-01
• Completion: 2012-01-01
• First posted: 2008-03-06
• Last updated: 2012-02-16

Locations

1 site across 1 country: China